

A Placebo-Controlled Trial of L-DOPA/Carbidopa in Early Cocaine Abstinence

Roger Wolfsohn, M.D., Michael Sanfilipo, M.S., and Burt Angrist, M.D.

Thirty patients with primary cocaine dependence who had used cocaine within the past 24 hours and were being admitted to a detoxification ward were rated for signs and symptoms of cocaine abstinence and craving. They then received four doses of either L-dihydroxyphenylalanine/carbidopa (100 mg/25 mg) or placebo over the next day. Ratings were repeated in the late afternoon

of the day of admission and after the final morning dose the next day. No significant differences in abstinence scores were found between the two treatment groups. The lack of drug-placebo differences appeared to be mainly due to rapid clearing of abstinence symptoms in the placebo-treated patients. [Neuropsychopharmacology 9:49-53, 1993]

KEY WORDS: L-DOPA; Cocaine; Cocaine abstinence; Clinical trial

It has been proposed that dopamine (DA) depletion "may underlie dysphoric effects of cocaine abstinence, and cocaine urges" (Dackis and Gold 1985). This hypothesis led to the use of dopaminergic agonists such as bromocriptine, amantadine, or L-dihydroxyphenylalanine (L-DOPA) to facilitate cocaine abstinence (Dackis et al. 1987; Kostin et al. 1988; Tenant and Sagherian 1987; Cocores et al. 1989).

In a prior open trial (Wolfsohn and Angrist 1990), we assumed that DA depletion would be maximal in the earliest phase of cocaine abstinence and administered L-DOPA/carbidopa (250 mg/25 mg, respectively) to eight cocaine-dependent patients who were entering a detoxification ward. Two doses were administered on the first hospital day. On the next day, six of the eight patients spontaneously reported that they had slept unusually well; all eight said they felt less anxious than after prior periods of cocaine discontinuation.

From the New York DVA Medical Center (RW, MS, BA), and Department of Psychiatry, New York University School of Medicine (BA), New York, New York.

Address correspondence to: Burt Angrist, Psychiatry 116A, New York DVA Medical Center, 423 E. 23rd St., New York, N.Y. 10010.

Received September 30, 1992; revised February 9, 1993; accepted February 9, 1993.

The patients were not on the ward at the same time and the consistency of the effects reported seemed greater than might be expected if placebo effects alone were involved. These promising results suggested the need for replication under placebo-controlled conditions.

METHODS

Subjects

Thirty patients who were entering a detoxification ward for primary cocaine dependence enrolled in our study after giving informed consent to participate. Cocaine use within the last 24 hours was required for inclusion. One subject, however, was included who had used cocaine 33 hours previously because he had prominent abstinence symptoms.

Subjects were excluded if they had been drinking heavily: had a positive morning admission breathalyzer test; acknowledged drinking eight cans of beer, three pints of wine, or one pint of distilled spirits daily; the admitting clinician felt that a chlordiazepoxide detoxification regimen was indicated. We chose these criteria rather than DSM III-R criteria for alcohol dependence because the latter emphasized inability to discontinue drinking, whereas the specific concern in this study was that alcohol withdrawal the first morning in the hospi-

tal would obscure cocaine abstinence symptoms. Lesser alcohol use and marijuana use were not exclusion criteria. Opiate-dependent subjects who required methadone detoxification were also excluded. One subject who had been on a methadone maintenance program for 10 years and was continuing maintenance was not excluded. Patients were also excluded if addicted to benzodiazepines or barbiturates or if they had medical conditions that would contraindicate L-DOPA administration, such as glaucoma, melanoma, endogenous psychotic disorders, cardiac arrhythmia, or any condition in which hypotension or vomiting would be potentially dangerous. Psychosis during cocaine intoxication was not cause for exclusion (Satel et al. 1990; Brady et al. 1991).

Procedures

If willing to participate, subjects had an electrocardiograph and breathalyzer test. They were then interviewed for a baseline rating of cocaine abstinence signs and symptoms (by RW). Immediately thereafter L-DOPA/carbidopa (100 mg/25 mg) or placebo was administered (between 9 AM and 11 AM). Active drug or placebo was repeated at 4 PM, 9 PM, and 8 AM the next day unless nausea or hypotension occurred. Repeated ratings were done (by both RW and BA) late the afternoon of admission (between 5 PM and 6 PM) and late the next morning (between 11 AM and Noon). For these ratings the patient was interviewed by both investigators and a consensus reached for each item of the scale.

Assessment of Cocaine Abstinence

Because no standardized instrument for quantifying cocaine abstinence exists, a scoring sheet was designed for this study. It assessed 1) the early abstinence pattern of dysphoria, irritability, anxiety, agitation, and combined desire for sleep and insomnia generally referred to as the "crash" (Kramer et al. 1967; Siegel 1982; Gawin and Kleber 1986); 2) depression; 3) anergia; and 4) craving. For the first three clusters, individual items representing both subjective and objective assessments were scored on a four-point scale corresponding to not present (0), mild (1), moderate (2), and severe (3). For craving, a global subjective score with the same anchor points (0 to 3) was used. The scoring sheet used is shown in Appendix A.

Statistical Analyses

Rating scale data were analyzed using a two-factor analysis of variance design, in which placebo-active drug group (two levels) was a between subjects factor and treatment period (three levels) was a within subjects

factor. Chi-square and *t*-tests were used to determine if placebo and active treatment groups differed with respect to any of the demographic variables.

RESULTS

Two patients were dropped after enrollment, and their ratings were not used in the data analysis. This decision was made because of the emergence of conditions that overshadowed symptoms of cocaine abstinence: opiate withdrawal in one patient and major depression with suicidality in the second. These two patients had been randomized to placebo and active drug, respectively. Thus the results presented are for two groups of 14 patients, who received either placebo or L-DOPA/carbidopa.

Clinical and demographic characteristics of the two patient groups did not differ. These are shown in Table 1.

Abstinence symptom scores were equivalent for the two treatment groups and showed a progressive decline over 24 hours in both groups. The rate of decline was similar for the two groups. None of the posttreatment ratings differed significantly between patients who received L-DOPA/carbidopa and those who received placebo. Combined subjective and objective (total) scores for "crash" phase measures, depression, and anergia and subjective ratings of cocaine craving are shown in Table 2.

Table 1. Demographic and Clinical Variables for the L-DOPA/Carbidopa and Placebo Groups

Demographic Variable	Treatment Group	
	Placebo	L-DOPA
Age	37.6	36.8
Race		
White	1	1
Black	13	11
Hispanic	0	2
Unemployed (%)	85.7	85.7
Undomiciled (%)	64.3	50.0
No. of convictions*	2.1	0.3
Years of drug use	8.7	8.1
No. of detoxifications	1.1	1.2
Money spent on cocaine/day (\$)	82.1	106.8
Hours before last drug use	12.6	13.6

There were no significant differences between the L-DOPA and placebo groups by *t*-test for continuous variables or chi-square for dichotomous variables.

* One placebo subject had 24 convictions. A *t*-test was inappropriate for this analysis. Mann-Whitney *U* = 87.0, *p* = .54.

Table 2. Means and Standard Deviations for Total "Crash" Phase Measures, Depression, Anergia, and Subjective Craving Scores by Treatment Group

Treatment Period	Crash		Depression	
	Placebo	L-DOPA	Placebo	L-DOPA
Baseline	5.64 ± 2.68	6.64 ± 1.95	4.43 ± 2.56	3.50 ± 2.18
First rating	3.93 ± 3.69	3.71 ± 2.20	3.00 ± 2.80	1.79 ± 2.19
Second rating	2.21 ± 1.89	2.43 ± 1.87	1.64 ± 2.34	0.86 ± 1.41

Treatment Period	Anergia		Craving	
	Placebo	L-DOPA	Placebo	L-DOPA
Baseline	7.00 ± 2.72	6.46 ± 2.93	1.50 ± 1.40	1.57 ± 1.28
First rating	6.79 ± 3.95	5.43 ± 3.57	0.71 ± 1.07	0.86 ± 1.10
Second rating	2.86 ± 3.70	3.93 ± 3.36	0.36 ± 0.84	0.50 ± 0.78

Analysis of variance showed no difference between placebo and active treatment groups for any given rating.

DISCUSSION

This placebo-controlled study failed to confirm the results

1990). The possible reasons are as follows. There were differences in the dosage schedules. In the initial trial, patients received two doses of L-DOPA 250 mg/carbidopa 25 mg, that is, cumulative doses of 500 mg L-DOPA and 50 mg carbidopa in a day. The present study used four doses of L-DOPA 100 mg/carbidopa 25 mg, that is, cumulative doses of 400 mg L-DOPA and 100 mg carbidopa. A difference of only 100 mg L-DOPA seems an unlikely explanation of the different findings in the two trials, particularly because a higher dose of carbidopa was administered in the second study. Another reason is that patients (and raters) were "fooled" in the first trial in that they wrongly attributed the rapid resolution of abstinence symptoms to the drug that was administered.

In this study, however, a similar rapid resolution of abstinence symptoms occurred in placebo-treated patients as in those who received active agent. This finding corresponds rather closely to a recent study of cocaine abstinence (Satel et al. 1991) in which the authors concluded "symptoms after inpatient cessation of uncomplicated cocaine addiction are relatively mild. . . . The findings

cal agents in the inpatient management of such patients."

The lack of a drug-placebo difference in this study could be interpreted as implying that either DA depletion does not contribute to the symptoms of cocaine abstinence or that the treatment used in this study did not affect the changes in DA system functioning that had occurred.

With respect to the first possibility, Satel et al. (1991) found only limited evidence for dysregulated dopa-

minergic function in their studies of plasma prolactin, growth hormone, and homovanillic acid during cocaine abstinence. On the other hand, preclinical and clinical data indicate some degree of dopaminergic dysregulation after cocaine exposure. In preclinical studies, persistent depletion of DA and its metabolites has been shown after a week of cocaine treatment (Wyatt et al. 1988). Glucose metabolism in DA-reward regions has been shown to be reduced by cocaine treatment and this reduction was reversed by bromocriptine (Clow and Hammer 1991). Similarly, cocaine self-administration has been shown to elevate thresholds for intracranial self-stimulation, a model of postcocaine anhedonia (Markou and Koob 1991), and this effect is also reversed by bromocriptine (Markou and Koob 1992). In clinical positron emission tomography studies, postsynaptic DA receptors have been shown to be diminished in cocaine abusers, particularly early in abstinence (Volkow et al. 1990).

The possibility that L-DOPA/carbidopa administration could not reverse changes in DA system function also cannot be dismissed lightly. Positron emission tomography studies with F-18-DOPA suggest diminished brain L-DOPA uptake after cocaine abuse (Baxter et al. 1988). Thus although administration of L-DOPA with decarboxylase inhibitors results in plasma L-DOPA levels many times greater than those which occur under physiologic conditions (Zurcher and Da Prada 1979; Da Prada 1984; Da Prada et al. 1987), brain uptake of L-DOPA may remain a limiting factor.

Finally, the design of this study, its findings and its limitations, need to be viewed in a larger context. A DA depletion hypothesis of cocaine addiction implies the possible therapeutic use of DA agonists. This study was designed to test whether L-DOPA/carbidopa could reverse cocaine abstinence signs and symptoms. We chose to study this question during the brief period

when stimulant abstinence symptoms are most prominent (Kramer et al. 1967; Siegel 1982; Gawin and Kleber 1986; Satel et al. 1991). The rapid clearing of indices of abstinence in our placebo-treated subjects precluded demonstrating a drug-placebo difference. However, this study cannot be considered a test of L-DOPA/carbidopa as a treatment for cocaine dependence, and it should be explicitly noted that the findings of this study in no way exclude a potential therapeutic role for L-DOPA or other DA agonists in cocaine addiction. A 24-hour inpatient trial is self-evidently quite different from an extended trial in outpatients in whom stressful life events, social problems, psychiatric problems, and conditioned cues might interact with dopaminergic dysregulation to increase relapse vulnerability (O'Brien et al. 1988). Thus a definitive trial of L-DOPA or any other therapeutic strategy as a treatment of cocaine addiction must be done in outpatients over clinically meaningful time periods.

ACKNOWLEDGMENTS

This study was approved by the Subcommittee for Human Subjects at the New York DVA Medical Center. We thank Merck Sharp and Dohme Research Laboratories for supplies of Sinemet 25/100 and matched placebo. We also thank the nursing staff of Ward 13N of the New York DVAMC for their assistance with this protocol.

REFERENCES

- Baxter LR, Schwartz JM, Phelps ME, Mazziotta JC, Barrio J, Rawson RA, Engel J, Guze BH, Selin C, Sumida R (1988): Localization of neurochemical effects of cocaine and other stimulants in the human brain. *J Clin Psychiatry* 49(Suppl 2):23-26
- Brady KT, Lydiard RB, Malcolm RM, Ballenger JR (1991): Cocaine-induced psychosis. *J Clin Psychiatry* 52:509-512
- Clow DW, Hammer RP (1991): Cocaine abstinence following chronic treatment alters cerebral metabolism in dopaminergic reward areas. *Neuropsychopharmacology* 4: 71-75
- Cocores JA, Gold MS, Pottash ALC (1989): Dopaminergic treatments in cocaine withdrawal. *Soc Neurosci Abstr* 15:251
- Da Prada M (1984): Peripheral decarboxylase inhibition: A biochemical comparison between benserazide and carbidopa. In Birkmayer W, Rinne VK, Worm-Peterson J, Dupont E, Schwarz W, (eds), *Parkinson's Disease: Actual Problems and Management*. Basel, Switzerland Editiones Roche, pp 25-38
- Da Prada M, Kettler R, Zurcher R, Schaffner R, Haefely WE (1987): Inhibition of decarboxylase and levels of DOPA and 3-9-methyldopa: A comparative study of benserazide versus Madopar HBS in volunteers. *Eur Neurol* 27(Suppl 1):9-20
- Dackis CA, Gold MS (1985): New concepts in cocaine addiction: The dopamine depletion hypothesis. *Neurosci Biobehav Rev* 9:469-477
- Dackis CA, Gold MS, Sweeney DR, Byron JP Jr, Climko R (1987): Single-dose bromocriptine reverses cocaine craving. *Psychiatry Res* 20:261-267
- Gawin FH, Kleber HD (1986): Abstinence symptomatology and psychiatric diagnoses in cocaine abusers. *Arch Gen Psychiatry* 43:107-113
- Kostin TR, Schumann B, Wright D (1988): Bromocriptine treatment of cocaine abuse in patients maintained on methadone. *Am J Psychiatry* 145:381-382
- Kramer JC, Fischman VS, Littlefield DC (1967): Amphetamine abuse pattern and effects of high doses taken intravenously. *JAMA* 201:305-309
- Markou A, Koob GF (1991): Postcocaine anhedonia: An animal model of cocaine withdrawal. *Neuropsychopharmacology* 4:17-26
- Markou A, Koob GF (1992): Bromocriptine reverses the elevation in intracranial self-stimulation threshold observed in a rat model of cocaine withdrawal. *Neuropsychopharmacology* 7:213-224
- O'Brien CP, Childress AR, Arndt IO, McLellan AT, Woody GE, Maany I (1988): Pharmacological and behavioral treatments of cocaine dependence: controlled studies. *J Clin Psychiatry* 49(Suppl 2):17-22
- Satel SL, Southwick SM, Gawin FH (1990): Clinical features of cocaine-induced paranoia. *Am J Psychiatry* 148:485-498
- Satel SL, Price LH, Palumbo JM, McDougale CJ, Krystal JH, Gawin F, Charney DS, Heninger GR, Kleber HD (1991): Clinical phenomenology and neurobiology of cocaine abstinence: A prospective inpatient study. *Am J Psychiatry* 148:1712-1716
- Siegel RK (1982): Cocaine smoking. *J Psychoactive Drugs* 14:321-337
- Tenant FS, Sagherian AA (1987): Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. *Ann Intern Med* 107:109-112
- Volkow ND, Fowler JS, Wolf AP, Schyler D, Shiue ChY, Alpert R, Dewey SL, Logan J, Bendriem B, Christman D, Hitzemann R, Henn F (1990): Effects of chronic cocaine abuse on postsynaptic dopamine receptors. *Am J Psychiatry* 147:719-724
- Wolfsohn R, Angrist B (1990): A pilot trial of levodopa-carbidopa in early cocaine abstinence. *J Clin Psychopharmacol* 10:440-442
- Wyatt RJ, Karoum F, Suddath R, Fawcett R (1988): Persistently decreased brain dopamine levels and cocaine. *JAMA* 259:2996
- Zurcher G, Da Prada M (1979): Radioenzymatic assay of femtole concentrations of DOPA in tissues and body fluids. *J Neurochem* 33:631-639

Appendix A. Cocaine Abstinence Symptoms Scoring Sheet

1. "Crash" Phase Measures

a. Subjective Rating

sweating _____
suspicious, fear of being
harmed _____
shaky, jittery, nervous,
restless _____
irritable, easily
angered _____
wants to sleep _____
can't sleep _____

b. Objective Rating

hypervigilant _____
agitation _____
overactivity _____

2. Depression:

sad, depressed,
hopeless _____
feels inadequate,
helpless, less
confident _____

tearful _____
sad expression _____

3. Anergia:

low energy, weak,
drained _____
tiredness, fatigue _____
don't care about
anything _____

motor retardation _____
decreased spontaneity _____
decreased reactivity _____

4. Cocaine craving _____

0 = none

1 = mild

2 = moderate

3 = severe, extreme